Dr. David Samadi on the Current State of Prostate Cancer in America and the Available Treatment Methods

Although prostate cancer is rampant among American men—aged 65 or older, it is among the least understood diseases. Thanks to urologists such as Dr. David Samadi, who have made it a goal to create awareness about prostate cancer and the available treatment methods.

Dr. David Samadi’s recent article on Huff Post is informative and scary in equal measure. The article, drawing statistics from the American Cancer Society, predicts over 164 thousand new cases of prostate cancer in 2018. Based on 2017’s statistics, over 29 thousand American men will succumb to death because of prostate cancer this year.

But Dr. David Samadi is convinced that early diagnosis and treatment of prostate cancer is the only proven way of beating back prostate cancer. Available treatment methods include surgery and radiation. Dr. David Samadi, however, recommends surgery over radiation, especially if the disease is localized. And he puts forward convincing reasons in support of his stance.

Radiation, in Dr. David Samadi’s view, is capable of causing secondary problems to a prostate cancer patients. Cases of rectal and bladder cancers developing after extensive radiation sessions are common. Dr. David Samadi suggests that if a prostate cancer patient chooses radiation and the disease proves to be stubborn, urologists find it challenging to administer surgical treatment procedures on such a patient. In addition, studies have demonstrated that prostate cancer patients treated with radiation are twice as likely to die sooner than the patients who opted for surgical procedures.

Closely related to the method of treatment is the experience of the physician administering the treatment. Dr. David Samadi advises prostate cancer patients to vet their urologist(s) thoroughly based on their experience and number of successful surgeries. Other factors include the physician’s commitment to urinary continence and sexual function after surgery or radiation.

Prominent men have beat cancer and are a testimony to the fact that prostate cancer is a treatable disease. Mitt Romney, Colin Powell, and John Kerry are popular politicians, who many people may be aware—or unaware—that they were diagnosed with prostate can and each chose surgery, and they are currently prostate cancer free.

Dr. David Samadi

Health care enthusiasts must be aware of Dr. David Samadi, as he frequently appears on television, internet, social media, etc. He is a respected urologist based at Lenox Hill Hospital; He is in charge of the medical facility’s urology and robotic surgery. Dr. David Samadi has dedicated his career to all matters prostate cancer, diagnosis and treatment.

Dr. David Samadi’s Facebook Page: www.facebook.com/DrDavidSamadi/

Eric Lefkofsky Offers Tempus to Help Fight Breast Cancer

Eric Lefkofsky is the founder of Groupon. But Eric Lefkofsky is behind the cancer-fighting startup Tempus too. Eric Lefkofsky is offering it to doctors at the University of Chicago. This way they can get data that will help them to treat the breast cancer patients in a much better way.Tempus is Chicago-based. It has recently announced its partnership with the University of Chicago Medicine Thursday. Tempus will provide molecular sequencing along with analysis. This will be provided to UChicago’s specialists in breast cancer. This will allow them to create customized treatment plans for their patients.

Tempus will be analyzing data from nearly 1,000 breast cancer patients. This will help the doctors as well researchers to uncover patterns that can help to predict how patients are going to respond to any specific treatment.Over time, such kind of data analysis will help in providing better treatment along with improved patient outcomes.

Eric Lefkofsky realized that even though breast cancer is one of the most common cancers, it has relatively little data on the millions of patients who are battling or have battled this disease. Hence many physicians are forced to make treatment decisions with no help coming from highly specific genetic information. Had this information been available, these physicians could have made better informed and targeted decisions. Hence partnering with Tempus with regard to this initiative is going to be really exciting. Physicians are quite eager to support all its efforts towards building the largest possible clinically annotated molecular data set that will be specific to breast cancer.

Tempus will be using machine learning along with genomic sequencing in order to help doctors in making real-time treatment decisions. This startup is headquartered in Chicago, where other ventures like Groupon, Lightbank as well as Drivin are also located.UChicago happens to be the latest in multiple partnerships being landed by Tempus in recent months. Other partnerships include working with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, besides the Mayo Clinic, as well as Rush University Medical Center. Others include Penn Medicine, besides the University of Michigan for fighting cancer.